A registrational clinical study of fruquintinib combined with an anti-PD-1 antibody in endometrial cancer patients
Latest Information Update: 04 Aug 2021
At a glance
- Drugs Antineoplastics (Primary) ; Fruquintinib (Primary)
- Indications Endometrial cancer
- Focus Registrational; Therapeutic Use
- Sponsors HUTCHMED
- 04 Aug 2021 New trial record
- 28 Jul 2021 According to a HUTCHMED media release, the company expects to initiate this study in the second half of 2021.